Angitia Biopharmaceuticals

Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of…